EP3740489 - PI4KIIIBETA INHIBITORS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 16.09.2022 Database last updated on 19.10.2024 | |
Former | Request for examination was made Status updated on 23.10.2020 | ||
Former | The international publication has been made Status updated on 27.07.2019 | ||
Former | unknown Status updated on 30.01.2019 | Most recent event Tooltip | 23.01.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states GlaxoSmithKline Intellectual Property Development Limited GSK Medicines Research Centre Gunnels Wood Road Stevenage SG1 2NY / GB | [2024/05] |
Former [2020/48] | For all designated states GlaxoSmithKline Intellectual Property Development Limited 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Inventor(s) | 01 /
BARTON, Nicholas Paul GlaxoSmithKline, Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB | 02 /
BERTRAND, Sophie Marie GlaxoSmithKline, Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB | 03 /
DOWN, Kenneth GlaxoSmithKline, Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB | 04 /
GRAY, Matthew GlaxoSmithKline, Gunnels Wood Road Stevenage, Hertfordshire SG1 2NY / GB | [2020/48] | Representative(s) | Telfer, Ruth Marie GSK Legal & Compliance - Global Patents 79 New Oxford Street London WC1A 1DG / GB | [N/P] |
Former [2020/48] | Telfer, Ruth Marie GlaxoSmithKline Global Patents, CN9.25.1 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Application number, filing date | 19700804.8 | 15.01.2019 | [2020/48] | WO2019EP50983 | Priority number, date | GB20180000734 | 17.01.2018 Original published format: GB 201800734 | GB20180017616 | 29.10.2018 Original published format: GB 201817616 | [2020/48] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019141694 | Date: | 25.07.2019 | Language: | EN | [2019/30] | Type: | A1 Application with search report | No.: | EP3740489 | Date: | 25.11.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.07.2019 takes the place of the publication of the European patent application. | [2020/48] | Search report(s) | International search report - published on: | EP | 25.07.2019 | Classification | IPC: | C07D487/04, A61P31/16, A61K31/519 | [2020/48] | CPC: |
C07D487/04 (EP,CN,IL,KR,US);
A61K31/519 (KR);
A61P11/00 (CN);
A61P11/02 (CN);
A61P11/06 (CN);
A61P27/16 (CN);
A61P31/04 (CN);
A61P31/12 (CN);
A61P31/16 (EP,CN,IL,KR);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/48] | Extension states | BA | 04.08.2020 | ME | 04.08.2020 | Validation states | MA | 04.08.2020 | Title | German: | PI4KIIIBETA-HEMMER | [2020/48] | English: | PI4KIIIBETA INHIBITORS | [2020/48] | French: | INHIBITEURS DE PI4KIIIBÊTA | [2020/48] | Entry into regional phase | 04.08.2020 | National basic fee paid | 04.08.2020 | Designation fee(s) paid | 04.08.2020 | Examination fee paid | Examination procedure | 04.08.2020 | Examination requested [2020/48] | 04.08.2020 | Date on which the examining division has become responsible | 24.02.2021 | Amendment by applicant (claims and/or description) | 20.09.2022 | Despatch of a communication from the examining division (Time limit: M04) | 26.01.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 12.01.2021 | Renewal fee patent year 03 | 20.01.2022 | Renewal fee patent year 04 | 19.01.2023 | Renewal fee patent year 05 | 23.01.2024 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2015110491 (APODEMUS AB [SE]); | [A]WO2016206999 (APODEMUS AB [SE]); | [A]WO2017055305 (UCB BIOPHARMA SPRL [BE], et al) | by applicant | GB2064336 | EP0069715 | GB2129691 | GB2169265 | GB2178965 | US4778054 | US4811731 | US5035237 | GB2242134 | WO9632099 | US5590645 | US5860419 | US5873360 | US6032666 | US6119853 | US6179118 | US6315112 | US6321747 | US6352152 | US6360739 | US6378519 | US6390291 | US6431168 | US6536427 | WO03061743 | US6679374 | WO2005044354 | WO2007012871 | WO2007068896 | US2011166147 | US8113199 | US8161968 | US8511304 | US8534281 | US8746242 | US9333310 |